Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

LOXO Insider Trading

LOXO | Market Equity

Comprehensive Trading Performance Summary

The investment history of corporate insiders at LOXO provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$0
Buys
$0
Sells

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2017-12-12 22:06 2017-12-08 Bonita David P Director SELL $82.50 250,000 $20,625,000 941,000 -21.0%
2017-12-12 22:02 2017-12-08 ORBIMED ADVISORS LLC Director SELL $82.50 250,000 $20,625,000 941,000 -21.0%
2017-11-30 01:25 2017-11-27 Burstein Jennifer Officer - Vice President of Finance OPT+S $74.82 1,700 $127,193 0 0.0%
2017-11-30 01:21 2017-11-27 Van Naarden Jacob Officer - Chief Business Officer OPT+S $74.50 3,082 $229,598 0 0.0%
2017-11-30 01:17 2017-11-27 Bilenker Joshua H. Director, Officer - President & CEO OPT+S $74.45 15,000 $1,116,749 182,707 0.0%
2017-11-28 03:29 2017-11-22 AISLING CAPITAL III LP 10% owner SELL $75.00 500,000 $37,500,000 3,688,920 -11.9%
2017-11-28 00:56 2017-11-22 MAYLEBEN TIMOTHY M Director OPT+S $75.85 3,000 $227,563 10,000 0.0%
2017-11-27 23:36 2017-11-22 Bonita David P Director SELL $75.00 267,000 $20,025,000 1,191,000 -18.3%
2017-11-27 23:30 2017-11-22 ORBIMED ADVISORS LLC Director SELL $75.00 267,000 $20,025,000 1,191,000 -18.3%
2017-11-23 01:05 2017-11-20 Flaherty Keith T. Director SELL $75.99 7,250 $550,922 9,732 -42.7%
2017-11-21 03:36 2017-11-16 Bonita David P Director SELL $74.26 270,000 $20,051,388 1,458,000 -15.6%
2017-11-21 03:31 2017-11-16 ORBIMED ADVISORS LLC Director SELL $74.26 270,000 $20,051,388 1,458,000 -15.6%
2017-11-07 01:03 2017-11-02 Kunkel Lori Anne Director SELL $84.91 5,000 $424,571 11,840 -29.7%
2017-11-02 00:08 2017-10-30 Burstein Jennifer Officer - Vice President of Finance OPT+S $87.19 1,700 $148,219 0 0.0%
2017-11-02 00:06 2017-10-30 Van Naarden Jacob Officer - Chief Business Officer OPT+S $86.89 3,082 $267,789 0 0.0%
2017-11-02 00:03 2017-10-30 Bilenker Joshua H. Director, Officer - President & CEO OPT+S $86.84 15,000 $1,302,669 188,707 0.0%
2017-10-19 00:03 2017-10-16 Naider Avi Z. Director SELL $90.00 5,000 $450,000 144,118 -3.4%
2017-09-21 00:09 2017-09-18 Burstein Jennifer Officer - Vice President of Finance OPT+S $89.10 1,700 $151,470 0 0.0%
2017-09-21 00:07 2017-09-18 Naider Avi Z. Director SELL $90.00 5,000 $450,000 149,118 -3.2%
2017-09-21 00:05 2017-09-18 Van Naarden Jacob Officer - Chief Business Officer OPT+S $89.00 3,082 $274,289 0 0.0%
2017-09-21 00:04 2017-09-18 Bilenker Joshua H. Director, Officer - President & CEO OPT+S $89.02 15,000 $1,335,276 188,707 0.0%
2017-09-16 00:06 2017-09-13 Naider Avi Z. Director SELL $90.00 5,000 $450,000 154,118 -3.1%
2017-08-24 01:35 2017-08-22 Kunkel Lori Anne Director SELL $75.17 10,000 $751,731 16,840 -37.3%
2017-08-24 01:33 2017-08-21 Flaherty Keith T. Director SELL $72.26 7,250 $523,884 16,982 -29.9%
2017-08-17 00:24 2017-08-14 Burstein Jennifer Officer - Vice President of Finance OPT+S $73.73 1,700 $125,347 0 0.0%
2017-08-17 00:22 2017-08-14 Van Naarden Jacob Officer - Chief Business Officer OPT+S $73.57 3,082 $226,753 0 0.0%
2017-08-17 00:20 2017-08-14 Bilenker Joshua H. Director, Officer - President & CEO OPT+S $73.56 15,000 $1,103,448 188,707 0.0%
2017-05-24 23:02 2017-05-22 Flaherty Keith T. Director SELL $45.09 7,250 $326,937 24,232 -23.0%
2017-02-24 00:34 2017-02-21 Flaherty Keith T. Director SELL $41.45 7,250 $300,517 31,482 -18.7%
2017-01-13 01:17 2017-01-10 AISLING CAPITAL III LP 10% owner BUY $31.00 160,000 $4,960,000 4,188,920 +4.0%
2016-12-22 01:30 2016-12-19 Flaherty Keith T. Director SELL $30.23 7,250 $219,168 38,732 -15.8%
2016-09-09 23:34 2016-09-07 Flaherty Keith T. Director SELL $30.00 14,500 $435,000 45,982 -24.0%
2016-08-13 00:05 2016-08-11 Flaherty Keith T. Director SELL $26.00 15,000 $389,967 60,482 -19.9%
2016-08-12 23:36 2016-08-10 ORBIMED ADVISORS LLC Director SELL $26.96 447,857 $12,074,225 1,728,000 -20.6%
2016-08-12 23:32 2016-08-10 Bonita David P Director SELL $26.96 447,857 $12,074,225 1,728,000 -20.6%
2016-05-19 23:24 2016-05-17 AISLING CAPITAL III LP 10% owner BUY $21.50 232,558 $4,999,997 4,028,920 +6.1%
2015-12-16 02:28 2015-12-11 AISLING CAPITAL III LP 10% owner BUY $27.50 200 $5,500 3,796,362 +0.0%
2015-11-20 03:51 2015-11-17 Naider Avi Z. Director BUY $26.50 3,773 $99,985 159,118 +2.4%
2015-11-20 01:34 2015-11-17 AISLING CAPITAL III LP 10% owner BUY $26.50 265,000 $7,022,500 3,796,182 +7.5%
2015-11-17 01:16 2015-11-12 AISLING CAPITAL III LP 10% owner BUY $27.65 78,669 $2,175,025 3,531,182 +2.3%
2014-08-07 00:01 2014-08-06 ORBIMED ADVISORS LLC 10% owner BUY $13.00 275,385 $3,580,005 2,175,857 +14.5%
2014-08-06 23:29 2014-08-06 Sonsini Peter W. 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:28 2014-08-06 Weller Harry R 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:28 2014-08-06 Viswanathan Ravi 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:27 2014-08-06 SANDELL SCOTT D 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:27 2014-08-06 MOTT DAVID M 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:27 2014-08-06 KOLLURI KRISHNA KITTU 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:26 2014-08-06 KERINS PATRICK J 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:26 2014-08-06 Florence Anthony A. Jr. 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
2014-08-06 23:26 2014-08-06 DRANT RYAN D 10% owner BUY $13.00 230,769 $2,999,997 1,789,420 +14.8%
SHOW ENTRIES
51-100 OF 110

How to Interpret $LOXO Trades

Not every insider transaction in LOXO is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $LOXO shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for LOXO

Insider activity data for LOXO is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $LOXO, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.